New hope for Hard-to-Treat myeloma? early trial of ABBV-438 begins

NCT ID NCT07409246

Recruiting now Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This early-stage trial tests an investigational drug called ABBV-438 in about 127 adults with multiple myeloma that has come back or stopped responding to treatment. The study has two parts: first, finding a safe dose, then testing that dose in more people. The main goal is to check safety and how the drug moves through the body, while also looking for signs that it might shrink the cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ABBV-438
What this could lead to: If successful, this could point toward a new treatment option for people with multiple myeloma that has stopped responding to other therapies.
What could go wrong: This is a very early Phase 1 trial, so the drug may not work or could have unexpected side effects. It is small and focused on safety, not proof of effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

City Of Hope - Atlanta /ID# 280294
RECRUITING

Newnan, Georgia, 30265, United States
City of Hope - Orange County Lennar Foundation Cancer Center /ID# 279067
RECRUITING

Irvine, California, 92618, United States
City of Hope National Medical Center /ID# 280273
RECRUITING

Duarte, California, 91010, United States
Colorado Blood Cancer Institute /ID# 280275
RECRUITING

Denver, Colorado, 80218, United States
Hadassah Medical Center-Hebrew University /ID# 278865
RECRUITING

Jerusalem, 91120, Israel
Institute of Hematology and Blood Diseases Hospital /ID# 279208
RECRUITING

Tianjin, Tianjin Municipality, 300020, China
Moffitt Cancer Center /ID# 279068
RECRUITING

Tampa, Florida, 33612, United States
START Midwest /ID# 279035
RECRUITING

Grand Rapids, Michigan, 49546, United States
Tel Aviv Sourasky Medical Center /ID# 279066
RECRUITING

Tel Aviv, Tel Aviv, 6423906, Israel
The Cancer Institute Hospital Of JFCR /ID# 279069
RECRUITING

Koto-ku, Tokyo, 135-8550, Japan
The Chaim Sheba Medical Center /ID# 279065
RECRUITING

Ramat Gan, Tel Aviv, 5265601, Israel

More trials for these conditions

Other studies related to the condition(s) this trial covers.